NIH-funded research R37 grant

Understanding how gut bacteria influence immune responses in cancer treatment

Official title: MAIT cell: microbiome crosstalk in antitumor immunity

Funded at University of Colorado Denver · NIH-11001213 · Data updated 2026-11-12

This study is looking at how the bacteria in your gut might influence how well certain cancer treatments work, especially by focusing on a special type of immune cell, and it aims to find out if specific gut bacteria can help doctors create more personalized treatment plans for patients.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionUniversity of Colorado Denver
NIH-funded
Lab location1 site (Aurora, UNITED STATES)
Project startDecember 15, 2023
Project endNovember 30, 2028
Funding year2025
Award (this year)$356,850
NIH project number5R37CA279604-02
Project IDNIH-11001213 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients with stage III or IV melanoma who are undergoing treatment with immune checkpoint inhibitors.

Less likely to help

Patients with early-stage melanoma or those not receiving immune checkpoint inhibitors may not benefit from this research.

What this research studies

This research investigates the relationship between gut microbiome composition and the effectiveness of immune checkpoint inhibitors in cancer patients, particularly focusing on a type of immune cell called MAIT cells. The study aims to uncover how these cells interact with microbial byproducts and how this interaction may affect cancer treatment outcomes. By analyzing patient samples, the researchers hope to identify specific microbial signatures that correlate with better responses to therapies like anti-PD-1. This could lead to personalized treatment strategies based on an individual's gut microbiome.

Why it matters

Potential benefit: If successful, this research could enhance the effectiveness of cancer immunotherapies by tailoring treatments based on gut microbiome profiles.

How similar studies have gone: Previous studies have shown promising results linking gut microbiome composition to immune responses in cancer treatment, suggesting that this approach could yield valuable insights.

Where this research is happening

  • University of Colorado Denver
    Aurora, United States
    Active

Researchers

  • Principal investigator: Tobin, Richard — University of Colorado Denver
  • Study coordinator: Tobin, Richard

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.